Rigel Pharmaceuticals, Inc.
RIGLHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeRigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. Valued at $750.1M, RIGL is a small-cap name in its sector. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.
Market Cap
$750.1M
Beta
1.13
P/E (TTM)
2.10
P/E (Fwd)
8.48
EPS (TTM)
$19.29
EPS (Fwd)
$4.78
ROE
174.1%
ROA
22.9%
Cash
$146.7M
Total Debt
$45.7M
Free CF
$78.6M
52W Change
115.6%
Annual Financials
Cash vs Debt
Rigel Pharmaceuticals, Inc. holds $146.7M in cash against $45.7M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow comes in at $78.6M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 174.1% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 22.9% further supports the picture of efficient asset utilization. Revenue has grown from $120.2M (2022) to $294.3M (2025), reflecting a 145% increase over the period.
With cash comfortably exceeding debt, RIGL has financial flexibility that may help navigate uncertain periods. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing RIGL.